Polygala tenuifolia for Health & Longevity - Quick Reference Sheet

Polygala tenuifolia for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Polygala tenuifolia is a traditional East Asian herb used as an oral supplement for memory, mood, and cognitive longevity. Standardized oral root extracts improve overall cognition in older adults and immediate verbal recall in younger adults, whereas depression and attention trials did not outperform placebo and evidence remains preliminary with conflicts of interest. Processed extracts administered orally after meals in split doses are well tolerated. (Full Review)

Protocol

Standardized cognitive extract regimen (BT-11 approach)
100 mg administered orally three times daily (300 mg/day)
Ethanolic root extract; used across youths, younger adults, older adults, and both sexes without adjustment.
Traditional decoction and multi-herb granules
3–10 g/day processed root or 2.5 g three times daily granules
Licorice-processed dried root (Zhi Yuanzhi) in decoctions (6–9 g twice daily in clinical protocols), or Kampo Kihito granules.
Time of day and meal timing
Immediately after breakfast, lunch, and dinner
Three-times-daily split dosing matches 1.5–4.7-hour metabolite half-lives; final dose with a late-afternoon meal if evening alertness occurs.
Time to effect
Memory and Cognitive Function in Healthy Adults
4–8 weeks
Human immediate verbal recall and CERAD cognitive gains in randomized trials (re-tested at 4 and 8–12 weeks).
Cognitive and Daily Function Support in Mild Cognitive Impairment and Alzheimer's Disease
16–52 weeks
Multi-herb formula clinical durations; cognitive scores returned toward baseline within 16 weeks after stopping Kihito.
Depressive Symptom Reduction
6–8 weeks
Mood and attention assessment window at 4 and 6–8 weeks (trials did not outperform placebo); rodent plasma peaks within 12 minutes.

Benefits

Contraindications
  • Active peptic ulcer disease, erosive gastritis, or clinically significant gastrointestinal disorders
  • Cardiac conduction abnormalities (QTc > 450 ms) or uncontrolled cardiovascular disease
  • Clinically significant hepatic or renal dysfunction, or severe anemia (hemoglobin < 10 g/dL)
  • History of epilepsy, seizure disorders, bipolar disorder, or psychosis
  • Pregnancy and lactation
  • Tamoxifen
Key Interactions
  • OATP2B1 substrate prescription medications (fexofenadine, rosuvastatin, fluvastatin, aliskiren)
  • P-glycoprotein substrate prescription medications (digoxin, dabigatran, cyclosporine, loperamide)
  • Monoaminergic antidepressants and stimulants (fluoxetine, venlafaxine, methylphenidate, selegiline)
  • Prescription acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)
  • Over-the-counter CYP2E1 substrates and mucolytics (mucus-thinning agents; acetaminophen, ethanol, chlorzoxazone, ambroxol)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin)
  • Cholinergic and monoaminergic supplements (huperzine A, citicoline, Bacopa monnieri, Rhodiola rosea, St. John's wort)
  • Fasting or empty-stomach administration

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal Irritation, Dyspepsia, and Dry Mouth; Mild Dizziness, Lethargy, and Tachycardia; Transient Liver Transaminase Elevation
  • Speculative: Raw Root Saponin Mucosal Toxicity and Gastric Hypomotility; Drug Transporter and Cytochrome P450 2E1 Inhibition

Monitoring

Marker Target Why
Alanine aminotransferase (ALT) & Aspartate aminotransferase (AST) ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) Safety check: detects transient hepatic transaminase elevation that requires pausing or stopping use.
Resting Heart Rate 60–100 beats/min (standard reference range) Safety check: identifies monoaminergic tachycardia (>100 beats/min) or palpitations that prompt dose reduction or discontinuation.
Validated Cognitive Battery (CERAD, MoCA, or K-CVLT) No established target; track improvement from the individual's own baseline score Efficacy marker: quantifies expected changes in global cognition, word list recognition, constructional recall, and immediate verbal recall.
Validated Mood or Attention Scale (MADRS or ADHD-RS-IV) No established target; track score reduction from the individual's own baseline Efficacy marker: evaluates symptom trajectory when used for mood or executive attention support.

Cadence: Baseline prior to initiation; at 1 week for resting heart rate and gastrointestinal tolerance; at 4 weeks, 6–8 weeks (mood/attention scales), and 8–12 weeks (cognitive battery and repeat hepatic panels, with hepatic check at 4–6 weeks for high-dose use); and every 6 months during extended supplementation.

Qualitative Assessment

  • Cognitive clarity: Word retrieval, name recall, and sustained task focus.
  • Gastrointestinal tolerance: Post-meal epigastric fullness, dry mouth, or dyspepsia.
  • Sleep and energy: Sleep onset latency, nighttime awakenings, and daytime alertness.